BRAF, erb-b2 receptor tyrosine kinase 2 (ERBB2), fibroblast growth factor receptor 2 (FGFR2), and isocitrate dehydrogenase 1 (IDH1) genes have been reported as therapeutically relevant genomic alterations in cholangiocarcinoma patients [12]. This evidence concerns the gene ERBB2 and cholangiocarcinoma.